ClinicalTrials.Veeva

Menu

The Preemptive Analgesic Efficacy of Nefopam

Seoul National University logo

Seoul National University

Status

Completed

Conditions

Breast Neoplasm

Treatments

Drug: Nefopam
Drug: Saline

Study type

Interventional

Funder types

Other

Identifiers

NCT02561468
Nefo_breast cancer

Details and patient eligibility

About

Nefopam is administered as a preemptive analgesic drug to the patient undergoing breast cancer surgery. It will be evaluated whether postoperative acute and chronic pain can be reduced.

Enrollment

94 patients

Sex

Female

Ages

20 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients diagnosed with breast cancer
  • Lumpectomy with axillary lymph node dissection or Lumpectomy with sentinel lymph node biopsy
  • American Society of Anesthesiologists physical status I or II

Exclusion criteria

  • Refusal
  • Seizure
  • Cardiac disease
  • Monoamine oxidase inhibitor user
  • Urologic disease
  • Glucoma
  • Preoperative analgesic drug medication
  • Pregnancy
  • Recurred breast cancer patient

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

94 participants in 2 patient groups, including a placebo group

Nefopam
Experimental group
Description:
20 mg nefopam in 100 ml normal saline is infused before starting operation.
Treatment:
Drug: Nefopam
Control
Placebo Comparator group
Description:
100 ml normal saline is infused before starting operation.
Treatment:
Drug: Saline

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems